Business
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel
About this update from Acrivon Therapeutics, Inc.
[{"type":"text","content":"Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data at the congress WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced an upcoming KOL panel on Friday, February 27, 2026, at 8:00 a.m. ET to discuss Acrivon’s ongoing registrational intent Phase 2b ACR-368 study in subjects with endometrial cancer and insights from a late-breaking oral presentation of ACR-368 clinical data at the upcoming ESGO Congress. The panel includes planned participation from globally recognized clinical investigators and thought leaders in the field of endometrial cancer, including: Ramez Eskander, M.D., Julie St. John endowed chair in gynecologic oncology, professor, department of obstetrics, gynecology and reproductive sciences, clinical trials medical director, fellowship director – gynecologic oncology, UCSD Health, Rebecca and John Moores NCI Designated Comprehensive Cancer CenterRobert L. Coleman, M.D., FACOG, FACS, special advisor to the president, GOG Advisors; vice president, GOG Foundation; Texas Oncology, US Oncology Network; CMO, Vaniam groupDomenica Lorusso, M.D., Ph.D., chair, the MITO (Multicenter Italian Trials in Ovarian Cancer and Gynecological Malignancies) Group; member of ENGOT (European Network of Gynecological Oncological Trial groups); director of gynecological oncology unit at Humanitas Hospital San Pio X, Milan; professor of obstetrics and gynecology, Humanitas University, RozzanoBrian Slomovitz, M.D., M.S., FACOG, member of the Board of Directors, GOG Foundation and the Uterine Cancer Lead, GOG Partners; director of gyneco...